Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic Leukemia
  • Phase

    Phase 1
  • Study Type

  • Status

    Unknown status
  • Study Participants

This is a single arm, open-label, multi-center study to determine the efficacy and safety of an experimental therapy called CART-19 in patients with chemo-refractory and relapsed B-cell ALL.
This is a single arm, open-label, multi-center, phase I study to determine the efficacy of CTL019 in patients with r/r B-cell ALL. The study will have the following sequential phases: Screening, Pre-Treatment (Cell Product Preparation & Lymphodepleting Chemotherapy), Treatment and Primary Follow-up, Secondary Follow-up (if applicable) and Survival Follow-up.
Study Started
May 31
Primary Completion
Dec 31
Last Update
Oct 14

Biological CART-19

2 to 5 x 10(6) autologous CART-19 transduced cells per kg body weight, with a maximum dose of 2.5 x 10(8) autologous CTL019 transduced cells via intravenous infusion.

Single dose of CART-19 Experimental

2 to 5 x 10(6) autologous CART-19 transduced cells per kg body weight, with a maximum dose of 2.5 x 10(8) autologous CTL019 transduced cells via intravenous infusion.


Inclusion Criteria:

Male and female subjects with CD 19+ B cell acute lymphoblastic leukemia in patients with no available curative treatment options (such as autologous or allogeneic SCT) who have limited prognosis (several months to <2 year survival) with currently available therapies will be enrolled

Age 1 to 60 years.
Expected survival > 12 weeks
Creatinine < 2.5 mg/dl and less than 2.5x normal for age
ALT ≤ 5x normal
Bilirubin <2.0 mg/dl
Any relapse after prior SCT will make patient eligible regardless of other prior therapy

Patients with relapsed disease after prior allogeneic SCT (myeloablative or non-myeloablative) will be eligible if they meet all other inclusion criteria and

①. Have no active GVHD and require no immunosuppression

②. Are more than 4 months from transplant

For those patients who require leukapheresis for T cell collection (i.e. no previously collected product exists), adequate venous access for apheresis or eligible for appropriate catheter placement, and no other contraindications for leukapheresis
Voluntary informed consent is given

Patients with CNS3 disease will be eligible if CNS disease is responsive to therapy (at infusion)

Exclusion Criteria:

Pregnant or lactating women. The safety of this therapy on unborn children is not known. Female study participants of reproductive potential must have a negative serum or urine pregnancy test performed within 48 hours before infusion
Uncontrolled active infection
Active hepatitis B or hepatitis C infection
Concurrent use of systemic steroids at the time of cell infusion or cell collection, or a condition, in the treating physician's opinion, that is likely to require steroid therapy during collection or after infusion. Steroids for disease treatment at times other than cell collection or at the time of infusion are permitted. Use of inhaled steroids, or hydrocortisone for physiological replacement in patients with adrenal insufficiency are permitted as well
Presence of grade 2-4 acute or extensive chronic GVHD
Under treatment for GVHD
Previous treatment with any gene therapy products
Any uncontrolled active medical disorder that would preclude participation as outlined.
HIV infection.
CNS3 disease that is progressive on therapy, or with CNS parenchymal lesions that might increase the risk of CNS toxicity
No Results Posted